** Shares of Caribou Biosciences CRBU.O rise 3% to 89 cents in extended trading
** Co says it is reducing workforce by 32% to extend its cash runway into H2 of 2027; as of March 31, co had about $212.5 mln in cash
** CRBU had 147 full-time employees as of March 1 - SEC filing
** Co says it will prioritize two cancer therapy programs, CB-010 and CB-011
** Also says it is stopping work on lupus and leukemia treatment trials
** As of last close, stock down 45% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.